Viscosupplementation Market Poised for Robust Growth, Projected to Hit US$ 13.6 Billion by 2032 at 10.8% CAGR

Market Overview: Trends, Size, and Regional Leadership

The global viscosupplementation market is witnessing significant momentum, primarily driven by the rising prevalence of osteoarthritis and the increasing preference for non-surgical treatment options. In 2021, the global market was valued at US$ 4.4 Bn, and it is projected to reach US$ 13.6 Bn by 2032, growing at an impressive CAGR of 10.8% during the forecast period (2022-2032). The market is fueled by the growing geriatric population, technological advancements in hyaluronic acid-based therapies, and increased patient awareness of alternatives to joint replacement surgery.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/33245

Among all product types, single-injection viscosupplements are expected to generate the highest revenue, offering an absolute dollar opportunity of nearly US$ 8.8 Bn during the forecast period. Orthopedic clinics and ambulatory surgical centers (ASCs) dominate the end-user segment, accounting for more than 60% of total revenue. Geographically, the Asia Pacific region leads the viscosupplementation market, capturing more than 45% of global revenue. This dominance is attributed to the region's aging population, rising osteoarthritis cases, and expanding access to outpatient orthopedic care in countries like India, China, and Japan.

✦ Key Highlights from the Report

✦ The global viscosupplementation market is expected to expand at a CAGR of 10.8% through 2032.
✦ Asia Pacific holds the highest revenue share, driven by its aging population and increased osteoarthritis incidence.
✦ Single-injection viscosupplements are leading the product segment with a growing preference for shorter treatment schedules.
✦ The U.S. market alone is forecasted to reach US$ 4.3 Bn by 2032, growing at 11.3% CAGR.
✦ Orthopedic clinics and ASCs dominate the end-user landscape due to the preference for outpatient procedures.
✦ Favorable reimbursement policies in the U.S. and France are boosting product adoption among elderly patients.

Market Segmentation: By Product Type and End User

The viscosupplementation market is segmented based on the type of injection-single-injection, three-injection, and five-injection regimens. Single-injection products currently lead the market, accounting for approximately 55% of global sales. Their popularity stems from benefits such as fewer hospital visits, quicker recovery times, and lower treatment costs. As regulatory bodies like the FDA continue to approve new single-injection formulations, patient preference for this segment is expected to strengthen further.

In terms of end users, the market is broadly divided into hospitals, orthopedic clinics, and ambulatory surgical centers (ASCs). Orthopedic clinics and ASCs dominate this space, generating more than 60% of market revenue in 2021. Their leadership position is driven by the increasing demand for same-day, non-invasive procedures for joint disorders. While hospitals also play a key role-particularly in emerging markets where orthopedic infrastructure is limited-clinics and ASCs offer more targeted, cost-effective, and quicker services for patients suffering from osteoarthritis.

Regional Insights: Global Expansion and Local Trends

Asia Pacific stands as the most lucrative region in the viscosupplementation market, projected to grow at the highest CAGR through 2032. This growth is anchored by a rapidly aging population, higher incidences of osteoarthritis, and increased healthcare accessibility in countries like China, India, and Japan. The region accounted for more than 45% of market revenue in 2020 and continues to be a hotspot for industry players aiming to expand their footprints.

The U.S. is another significant market, with a projected valuation of US$ 4.3 Bn by 2032 and a CAGR of 11.3%. Factors contributing to this growth include the prevalence of lifestyle-related joint conditions, robust reimbursement policies, and a higher rate of FDA approvals. Similarly, the U.K. market is poised to grow at 12.3% CAGR, while Japan's market is forecasted to expand at a remarkable 14.1% CAGR. South Korea also demonstrates strong potential with an expected CAGR of 9.8%, driven by the country's advanced healthcare system and increasing demand for outpatient care.

Market Drivers

One of the most prominent drivers of the viscosupplementation market is the rising demand for non-surgical alternatives to treat osteoarthritis. As a degenerative joint disease that primarily affects individuals over the age of 30, osteoarthritis is increasingly prevalent due to extended life expectancy and lifestyle changes. Hyaluronic acid-based injections provide relief from joint pain and improve mobility without the need for invasive procedures. In addition, continuous product innovations, such as the development of single-injection regimens, are attracting a broader patient base. Government support in the form of favorable reimbursement policies further accelerates adoption, especially among elderly patients.

Market Restraints

Despite its promising growth trajectory, the viscosupplementation market faces several restraints. Chief among these is the high cost of treatment, which remains a barrier in low- and middle-income countries. In regions where insurance coverage is limited or inconsistent, patients are less likely to opt for viscosupplementation, especially when alternative pain management methods are more affordable. Furthermore, the availability of corticosteroid injections and over-the-counter anti-inflammatory medications poses stiff competition. Limited awareness and access in rural areas also hamper market penetration, making education and outreach efforts critical.

Market Opportunities

The viscosupplementation market presents numerous opportunities for expansion. As clinical trials continue to show favorable outcomes for newer, longer-lasting formulations, there is potential for increased product differentiation. Emerging markets, particularly in Asia Pacific and Latin America, offer untapped potential due to rising disposable incomes and improving healthcare infrastructure. Technological innovations in drug delivery and imaging techniques also provide opportunities to improve treatment efficacy and patient comfort. Additionally, as regulatory bodies approve more products for additional joints beyond the knee-such as the hip and shoulder-the market scope is likely to broaden significantly.

Reasons to Buy the Report

✔ Comprehensive insights into current and future market trends, growth drivers, and challenges.
✔ Detailed segmentation analysis that highlights revenue opportunities across product types and end-users.
✔ Regional insights with market data for North America, Europe, Asia Pacific, and other key markets.
✔ Competitive landscape profiling key players, their market share, and recent strategic developments.
✔ Identification of emerging opportunities and market entry strategies for new and existing players.

Company Insights: Key Players and Recent Developments

• Sanofi
• Anika Therapeutics, Inc.
• Seikagaku Corp.
• Zimmer Biomet
• Smith & Nephew PLC
• Ferring Pharmaceuticals B.V.
• Lifecore Biomedical
• LG Life Sciences Ltd.
• Fidia Farmaceutici S.p.A.
• F. Hoffmann-La Roche Ltd.

Recent Developments:

In April 2018, Bone Therapeutics S.A. completed clinical trials for its JTA-004 intra-articular injection, aimed at treating knee osteoarthritis.
In June 2019, Anika Therapeutics, Inc. launched Hyalofast, a hyaluronic acid-based cartilage repair scaffold, at the International Cartilage Regeneration and Joint Preservation Society (ICRS).

Conclusion

The viscosupplementation market is experiencing a robust growth phase, spurred by the increasing prevalence of osteoarthritis, rising demand for non-surgical treatments, and technological advancements in hyaluronic acid-based products. With favorable reimbursement policies, growing geriatric populations, and a strong pipeline of innovative therapies, the market is poised for further expansion. Although challenges such as high treatment costs and limited awareness persist, the opportunities for growth in emerging economies and across new joint applications remain significant. As global healthcare shifts towards more personalized, outpatient-oriented care, viscosupplementation is set to become an even more integral component in the management of degenerative joint diseases.

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web:
https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.